Table 2 Clinical and biologic features... | American Society of Hematology

Table 2

Clinical and biologic features of the patients with CLL studied

Patient with CLL	Age, y	Rai stage*	Binet stage*	Clinical course	Follow-up, mo	HC	LC	CD38, %†	ZAP70, %†‡	IGHV, %	HS1 hyperphospho§
1	68	2	A	Progressive	123 (alive)	D	λ	3.68	Pos	100	Yes
2	60	0	A	Progressive	196 (dead)	MD	Neg	0.70	Pos	91.67	Yes
3	68	0	A	Stable	56 (alive)	MD	κ	1.81	Neg	100	No
4	69	0	A	Progressive	120 (lost)	MD	Neg	1.2	Pos	100	No
5	78	0	A	Stable	101 (lost)	MD	κ	0.4	Neg	89.5	No
6	53	1	B	Stable	159 (lost)	MD	κ	0.1	Neg	96.2	No
7	78	0	A	Progressive	180 (dead)	MD	λ	88.5	Neg	100	Yes
8	73	0	A	Progressive	117 (lost)	MD	κ	78	Neg	100	Yes

Patient with CLL	Age, y	Rai stage*	Binet stage*	Clinical course	Follow-up, mo	HC	LC	CD38, %†	ZAP70, %†‡	IGHV, %	HS1 hyperphospho§
1	68	2	A	Progressive	123 (alive)	D	λ	3.68	Pos	100	Yes
2	60	0	A	Progressive	196 (dead)	MD	Neg	0.70	Pos	91.67	Yes
3	68	0	A	Stable	56 (alive)	MD	κ	1.81	Neg	100	No
4	69	0	A	Progressive	120 (lost)	MD	Neg	1.2	Pos	100	No
5	78	0	A	Stable	101 (lost)	MD	κ	0.4	Neg	89.5	No
6	53	1	B	Stable	159 (lost)	MD	κ	0.1	Neg	96.2	No
7	78	0	A	Progressive	180 (dead)	MD	λ	88.5	Neg	100	Yes
8	73	0	A	Progressive	117 (lost)	MD	κ	78	Neg	100	Yes

HC indicates heavy chain; LC, light chain; D, IgD surface expression; and MD, IgM/IgD surface expression

Determined at diagnosis.

Determined by flow cytometry.

Positive (pos) or negative (neg) was determined with a cutoff of 20%.

Number of spots shown on silver-stained 2-dimensional gels.